June 24, 2008
A study recently reported in the journal, AIDS, found that people who started taking HIV medicines with higher CD4 cell counts were more likely to have their immune systems restored to near normal levels. This study adds to a growing body of data on the benefits of early anti-HIV treatment.
The study participants were 75% male and 63% white. About half were men who have sex with men, 35% heterosexual and 4% injection drug users. Average CD4 count at the start when starting HIV treatment was 190. Just under 20% started with CD4 counts under 50, while only 7% started with counts above 500.
Most people in the cohort experienced significant increases in their CD4 counts. Not surprisingly, there was a very strong relationship between a person's CD4 cell count when they started and their likelihood of achieving a count of over 800. Those who started treatment with CD4 counts over 500 were over 23 times more likely to achieve counts of 800 than people who started with counts below 50.
The difference was also significant for groups with much smaller differences in their CD4 counts before starting therapy. Those who started with counts between 350-500 were 2.76 times more likely to achieve counts above 800 than those who started with counts between 200-350.
The same was seen in people with highest and lowest counts when they started. For example, people who started treatment with CD4 counts between 50 and 200 were about twice as likely as those who started below 50 to achieve counts above 800. Likewise, people who started with counts above 500 were 2.4 times more likely than those who started between 200 and 350.There were several other interesting findings:
The affects of age on treatment outcomes is of growing importance. As we age, our immune systems' ability to recover wanes. This study highlights this fact and argues for earlier treatment for people over 50 living with HIV.
This study will add to the ongoing debate on the best time to start HIV treatment. The current Federal Guidelines recommend starting treatment before your CD4 count falls to 350. It also discusses the possible benefits and risks of starting at higher CD4 counts, but does not make a recommendation.
Without a large, definitive study aimed at determining the best time to start treatments, doctors, activists and people with HIV have to piece together results from other studies, like this one, to guide them on this important question. If one of the main goals of HIV treatment is to restore a person's immune system to as close to normal as possible, this study strongly supports earlier treatment. This potential benefit must be weighed against the risks and difficulties of HIV treatment. This equation is growing more favorable toward earlier treatment as HIV drugs become more tolerable and convenient.